Abstract: Provided are a crystal form and amorphous form of carebastine p-toluenesulfonate, and a preparation method therefor, relating to the field of medicinal chemistry, for use in solving the problems in the prior art that carebastine is unstable, not easy to scale up for synthesis, and difficult to make into a drug and the like. The crystal form and amorphous form of carebastine p-toluenesulfonate have the characteristics of high purity, high stability, high bioavailability, easy scale-up synthesis, and industrial production and the like, and have excellent hygroscopicity for easy storage.

Abstract: The disclosure discloses a method for treating a plasma sample containing (7aS,2?S)-2-oxo-clopidogrel and a method for determining the same, which belongs to the technical field of pharmaceutical analysis and solves the problem in the prior art that there is not yet a method for determining the concentration of (7aS,2?S)-2-oxo-clopidogrel in plasma. The method for treating a plasma sample containing (7aS,2?S)-2-oxo-clopidogrel comprises: taking whole blood containing (7aS,2?S)-2-oxo-clopidogrel, adding a reducing agent solution and collecting plasma. The method for determining (7aS,2?S)-2-oxo-clopidogrel in plasma according to the disclosure uses the treatment method as described above to treat a sample to be determined, and includes the following steps: S1. Whole blood treatment: taking whole blood, adding a reducing agent solution, centrifuging, and collecting plasma; S2.

Abstract: The present invention relates to a composition for treating and resisting blood coagulation and use thereof, and particularly relates to a pharmaceutical composition containing (7aS, 2'S)-2-oxo-clopidogrel and use thereof. The present invention provides a medicinal specification of a solid preparation which, after oral administration before/after meals for use in healthy adults, can be similar to clopidogrel bisulfate tablets that are 12.5 times larger in specification in terms of Cmax, AUC(0-t), and AUC(0-?) of a metabolically produced compound A and an active metabolite H4, thereby ensuring the effectiveness and safety of usage of medication.

Abstract: The present invention discloses a carebastine salt and a use of the carebastine salt, relates to the field of pharmaceutical chemistry, and solves the problems of carebastine in the related art such as poor solid form, excessive impurities, instability, difficulty in purification, difficulty in scale-up synthesis, and unsuitability for medicinal use. The carebastine salt of the present invention includes, but is not limited to, acid addition salts or base addition salts, and particularly includes potassium salts, sodium salts, methanesulfonate and p-toluenesulfonate. The carebastine salt of the present invention has the use of preparing histamine H1 receptor antagonist drugs. The carebastine salt of the present invention has the characteristics such as easy purification, high stability, simple process and easy industrial production, and has good hygroscopicity characteristics and is convenient for storage.

Abstract: Provided are an anti-platelet aggregation medicament and use thereof. The medicament is a compound having a structure of formula I, or a pharmaceutically acceptable salt thereof, a solvate thereof, or a deuterated substance thereof. The compound has a remarkable anti-platelet aggregation effect, relatively suitable water solubility and good stability, and thus is expected to become a new type of injectable anti-platelet aggregation medicament.

Abstract: Disclosed are a dihydropyrimidine based compound, a preparation method therefor and an application thereof, belonging to the technical field of pharmaceutical chemistry. The present disclosure relates to a dihydropyrimidine based compound, the structure of which is shown in formula I. Also provided in the present disclosure is an application of the compound represented by formula I, or a salt, solvate, isomer, metabolite, nitrogen oxide and prodrug thereof, in the preparation of a medicament for treating or preventing P2X3 and/or P2X2/3 receptor-related diseases. The dihydropyrimidine based compound of the present disclosure has good P2X3 receptor antagonist activity and improved safety.

Abstract: The present disclosure discloses sulfonamides, methods for preparation thereof and uses thereof, belonging to the technical field of medicinal chemistry. The structure of the sulfonamides of the present disclosure is shown in Formula I. The present disclosure also provides use of the compound of Formula I or a salt, solvate, isomer, metabolite, nitrogen-oxide, or prodrug thereof in the manufacture of a medicament for the treatment or prevention of P2X3 and/or P2X2/3 receptor-associated diseases. The sulfonamides of the present disclosure have a potent cough suppressing effect and a significantly prolonged action. Their inhibitory activity against P2X3 is superior to that of Comparative compound 1 and the positive control Gefapixant.